Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | ILK | Q13418 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25401469 | 0.85 | TDP1 (0.53) | TDP1HSP90AA1ESR2NPC1RAB9A | |
| SCHEMBL14994140 | 0.84 | LCK (0.46) | KMT2AILKCHEK2 | |
| Hydrochloric Acid SCHEMBL29690574 | 0.82 | CHEK2 (0.44) | KMT2AILKCHEK2 | |
| SCHEMBL23081015 | 0.81 | HTT (0.56) | TDP1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL30620060 | 0.79 | MAPT (0.58) | TDP1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL21486454 | 0.78 | NPC1 (0.50) | TDP1NPC1ALDH1A1HPGDLMNA | |
| Trifluoroacetic Acid SCHEMBL29690632 | 0.78 | CHEK2 (0.41) | SMN1; SMN2ILKCHEK2 | |
| SCHEMBL5696651 | 0.71 | TDP1 (0.77) | TDP1HSP90AA1ESR2NPC1RAB9A | |
| SCHEMBL21723107 | 0.71 | TDP1 (0.77) | TDP1HSP90AA1ESR2NPC1RAB9A | |
| SCHEMBL939189 | 0.71 | TDP1 (0.53) | TDP1HSP90AA1ESR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4479137-A1 | IRAK4 INHIBITORS | Astrazeneca AB (SE) | 2024-12-25 | — | — | EP | disclosed |
| US-11866405-B2 | Substituted indazoles as IRAK4 inhibitors | ASTRAZENECA AB (SE) | 2024-01-09 | — | — | US | disclosed |
| CN-116940572-A | 2H-indazole derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023152349-A1 | IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2023-08-17 | — | — | WO | disclosed |
| CN-116583285-A | N- (imidazo [1,2-b ] pyridazin-3-yl) -1-cyclohexyl-2H-indazole-5-carboxamide and N- (pyrazolo [1,5-a ] pyrimidin-3-yl) -1-cyclohexyl-2H-indazole-5-carboxamide derivatives as IRAK4 inhibitors for the treatment of asthma | 阿斯利康(瑞典)有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20220185817-A1 | IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | US | disclosed |
| CN-114585609-A | 2H-indazole derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021038419-A1 | KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT | INSILICO MEDICINE IP LIMITED (CN) | 2021-03-04 | — | — | WO | disclosed |
| EP-1737857-A1 | PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | TDP1 714/4885HSP90AA1 3561/4885ESR2 3101/4885 |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | TDP1 334/4885HSP90AA1 819/4885ESR2 3599/4885 |
| US-11866405-B2 | Substituted indazoles as IRAK4 inhibitors | IRAK4, IRAK1, IRAK3 | TDP1 717/4885HSP90AA1 3713/4885ESR2 2242/4885 |
| US-20220185817-A1 | IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | TDP1 805/4885HSP90AA1 3464/4885ESR2 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.